Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target "novel transcript, antisense to HNRNPLL" (ENSG00000296297) is an uncharacterized transcript identified in genomic databases as antisense to the protein-coding gene HNRNPLL. There is no evidence in current research or annotation that this transcript encodes a protein or acts as a receptor, enzyme, transporter, or pharmacological target. No functional, disease, or therapeutic relevance is documented for this transcript, and it does not appear in lists of canonical biological targets[3][2][1]. The principal protein-coding gene at this locus, HNRNPLL (heterogeneous nuclear ribonucleoprotein L-like), is a well-studied RNA-binding protein involved in alternative splicing, but the antisense transcript itself remains uncharacterized and non-canonical as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to HNRNPLL (ENSG00000296297).